|
KMID : 1030220180190020088
|
|
Journal of Korean Diabetes
2018 Volume.19 No. 2 p.88 ~ p.96
|
|
|
Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease
|
|
Yang Hye-Kyung
Park Cheol-Young
|
|
|
Abstract
|
|
|
|
Nonalcoholic fatty liver disease (NAFLD) is more prevalent in diabetic patients than in non-diabetic subjects, because the two diseases share a common pathophysiological mechanism. Associated abnormalities can be observed from the pre-diabetic stage. Lifestyle intervention, including diet, exercise, and weight loss, is the primary recommended therapy for NAFLD. Among the therapeutic drugs for NAFLD treatment, anti-diabetic agents are aimed at improving or slowing the progression of NAFLD in addition to lowering blood glucose. In this paper, we systemically review the evidence surrounding antidiabetic medications and their ability to improve disease progression in patients with NAFLD.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, Glucose-lowering agents, Incretins, Nonalcoholic fatty liver disease, Sodium-glucose transporter 2, Thiazolidinediones
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|